Measurement of cardiac natriuretic hormones (atrial natriuretic peptide, brain natriuretic peptide, and related peptides) in clinical practice: The need for a new generation of immunoassay methods

Clinical Chemistry

Volumn 46, Issue 10, 2000, Pages 1529-1534

  Clerico, A ^a   Del Ry, S ^a   Giannessi, D ^a  

^a INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE;

ACUTE HEART INFARCTION; CLINICAL PRACTICE; DIAGNOSTIC ACCURACY; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART FAILURE; HEMODIALYSIS; HUMAN; INTERMETHOD COMPARISON; LUMINESCENCE; PROGNOSIS; QUANTITATIVE DIAGNOSIS; RADIOIMMUNOASSAY; SHORT SURVEY;

EID: 0033775410     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/46.10.1529     Document Type: Short Survey

References (40)

1. Natriuretic peptides: Physiology, therapeutic potential, and risk stratification in ischemic heart disease
2. Measurement and significance of circulating natriuretic peptides in cardiovascular diseases
3. Pathophysiologic relevance of measuring the plasma levels of cardiac natriuretic peptide hormones in humans
4. Immunoassay methods for the measurement of natriuretic cardiac hormones (ANP, BNP, and related peptides) in humans
5. Plasma concentrations of brain natduretic peptide: Will this new test reduce the need for cardiac investigations?
6. Brain natduretic peptide versus atrial natriuretic peptide - Physiological and pathophysiological significance in children and adults: A review
7. Mechanical and neuroendocrine regulation of the endocrine heart
8. Molecular forms of circulating atrial natriuretic peptides in human plasma and their metabolites
9. Three peptides from the atrial natriuretic factor prohormone amino terminus lower blood pressure and produce diuresis, natriuresis, and/or kaliuresis in humans
10. Processing of kaliuretic peptide in human plasma and serum
11. Processing of long-acting natriuretic peptide and vessel dilator in human plasma and serum
12. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): A new marker of cardiac impairment
13. Cardiac peptide stability, aprotinin and room temperature: Importance for assessing cardiac function in clinical practice
14. Development and validation of a two-site immunoradiometric assay for human atrial natriuretic factor in unextracted plasma
15. Immunoradiometric assay of atrial natriuretic peptide in unextracted plasma
16. Stability of human atrial natriuretic peptide in blood samples
17. Analytical performance and clinical usefulness of a commercially available IRMA kit for the measurement of atrial natriuretic peptide in patients with heart failure
18. An immunoradiometric assay for brain natriuretic peptide in human plasma
19. Circulating levels of cardiac natriuretic peptides (ANP and BNP) measured by highly sensitive and specific immunoradiometric assays in normal subjects and in patients with different degrees of heart failure
20. Measurement of brain natriuretic peptide in plasma samples and cardiac tissue extracts by means of an IRMA method
21. The N-terminus, a 4,000-MW peptide from the midportion of the N-terminus of the atrial natriuretic factor prohormone each circulate in humans and increase in congestive heart failure
22. N-terminal atrial natriuretic peptide and atrial natriuretic peptide in human plasma: Investigation of plasma levels and molecular circulating form(s) using radioimmunoassays for pro-atrial natriuretic peptide (31-67), pro-atrial natriuretic peptide (1-30) and atrial natriuretic peptide (99-126)
23. Analysis of peptides derived from pro-atrial natriuretic peptide that circulate in man and increase in heart disease
24. Immunoradiometric assay for N-terminal fragment of proatrial natriuretic peptide (N-terminal proANP) in human plasma
25. An immunoluminometric assay for N-terminal pro-brain natriuretic peptide: Development of a test for left ventricular dysfunction
26. Development of a novel, N-terminal-proBNP (NT-proBNP) assay with a low detection limit
27. Comparison of atrial natriuretic peptide, B-type natriuretic peptide, and n-terminal proatrial natriuretic peptide as indicators of left ventricular systolic dysfunction
28. Adrenomedullin, endothelin, neuropeptide Y, atrial, brain, and C-natriuretic prohormone peptides compared as early heart failure indicators
29. Evaluation of plasma natriuretic peptides as markers for left ventricular dysfunction
30. Plasma cardiac natriuretic peptide determination as a screening test for the detection of patients with mild left ventricular impairment
31. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care
32. Natriuretic peptides - Relevance in cardiovascular disease
33. Biochemical detection of left-ventricular systolic dysfunction
34. An experimental study of cardiac natriuretic peptides as marker of development of congestive heart failure
35. Neuroendocrine prediction of left ventricular function and heart failure after acute myocardial infarction
36. Plasma vasoactive peptides after acute myocardial infarction in relation to left ventricular dysfunction
37. Vasoactive peptide release in relation to hemodynamic and metabolic changes during rapid ventricular pacing
38. Demography and epidemiology of cardiovascular disease in old age
39. Clinical evaluation of the triage B-type natriuretic peptide assay for point of care testing of patients with congestive heart failure
40. Current status and performance goals for serum thyrotropin (TSH) assays